This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Atrioventricular Septal Defect (AVSD / Endocardial Cushion Defect)방실중격결손

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: Q21.2 | Special Copayment Reduction: V269 (rare disease Special Copayment Reduction)
B. SynonymsAtrioventricular septal defect, Total AV Canal, Endocardial Cushion Defect, Ostium Primum ASD (type I atrial septal defect)
C. Adult onsetLikelihood of first presentation in adulthood low to moderate — the complete form is mostly diagnosed in infancy with heart failure. The partial form (primum ASD) may remain asymptomatic until school age or adulthood when the defect is small or atrioventricular valve regurgitation is mild, and is sometimes first diagnosed because of exercise intolerance, atrial arrhythmias, or pulmonary hypertension.
1. History1954 first corrective attempt with extracorporeal circulation → 1968–1980s development of single-/two-patch techniques → standardization of early repair in Down syndrome → early repair (age 3–6 months) currently recommended.
2. CausesAbnormal endocardial cushion development at embryonic weeks 4–6. Complete form (common atrioventricular valve + primum defect + inlet VSD) vs partial form (primum ASD + cleft mitral valve). Strongly associated with Down syndrome (trisomy 21).
3. GeneticsOverexpression of DSCAM and COL6A in Down syndrome. Non-syndromic: GATA4, GATA6, CRELD1, NKX2.5, EVC/EVC2 variants. Familial recurrence rate about 3–14%. Chromosome testing recommended in all patients.
4. General epidemiologyAbout 4–5% of congenital heart disease. Down syndrome present in 60–70% of patients with complete AVSD. About 1 in 2,000–5,000 live births. Korean Special Copayment Reduction V269.
5. PathophysiologyAtrial and ventricular left-to-right shunt → increased pulmonary blood flow → pulmonary hypertension. Rapid pulmonary vascular response in Down syndrome. Atrioventricular valve regurgitation → volume overload. Progression to Eisenmenger physiology if uncorrected.
6. SymptomsComplete form: heart failure within weeks to months (tachypnea, feeding difficulty, failure to thrive). Partial form: mild exercise intolerance or asymptomatic. Recurrent pulmonary infections. Cyanosis with Eisenmenger physiology.
7. SignsCardiomegaly, left axis deviation (ECG), systolic murmur, fixed splitting of S2. Accentuated P2 and disappearance of the murmur as pulmonary hypertension progresses. Increased pulmonary vascularity on chest X-ray.
8. ScreeningDetailed prenatal fetal echocardiography (18–22 weeks). Newborns with confirmed Down syndrome: echocardiography within 1–2 months of birth. CCHD screening (oxygen saturation). Fetal echocardiography if there is a family history.
9. DiagnosisEchocardiography (defect anatomy, Rastelli classification, valve regurgitation, estimation of pulmonary pressure). Cardiac catheterization (PVR measurement). Chromosomal microarray (to identify Down syndrome, etc.). Cardiac CT (to identify associated malformations).
10. TreatmentComplete form: complete repair within 3–6 months of birth (two-patch or modified single-patch technique). Atrioventricular valve reconstruction is key. Medical treatment of heart failure before surgery. Eisenmenger: targeted therapy for pulmonary hypertension.
11. PrognosisEarly mortality after early repair 1–3%. 10-year survival 85–95%. Reoperation (residual atrioventricular valve regurgitation, LVOTO) 10–15%. Long-term follow-up essential.
12. PreventionEarly diagnosis by prenatal fetal echocardiography. Early echocardiography in newborns with Down syndrome. Prevention of pulmonary hypertension by complete repair within 3–6 months of birth. Regular postoperative follow-up.
13. ReferencesList of 10 key references

1. History

Atrioventricular Septal Defect (AVSD) was formerly called endocardial cushion defect or atrioventricular canal, and understanding of this disease deepened along with advances in cardiac embryology. In the mid-19th century, pathologists began describing hearts at autopsy with combined defects of the atrial and ventricular septa and atrioventricular valve malformations, and the concept that this complex malformation arises from a single developmental unit was established in the early 20th century.

In 1936 Louis Lev and later, in 1954, Roger Van Praagh systematically described the developmental role of the endocardial cushions, greatly improving the pathoanatomical understanding of this defect. During normal development, the endocardial cushions form the lower part of the atrial and ventricular septa and the base of the atrioventricular valves, and it was established that abnormal development of these structures is the cause of AVSD.

In the history of surgical treatment, Richard Varco and John Kirklin performed early corrective operations using cardiopulmonary bypass between 1954 and 1958, but mortality was high. Surgical outcomes improved as Warden of Denmark in 1968, and later Donald Neville New of Australia and others in the 1970s, refined the single-patch technique. In the 1970s–80s, the two-patch technique and later the modified single-patch technique were introduced and developed into the current standard repair methods.

The association between AVSD and Down syndrome (trisomy 21) has been clinically recognized since the 1950s; congenital heart disease occurs in about 40–45% of patients with Down syndrome, and AVSD is the most common among them (about 40%). This association is currently understood to result from overexpression of cardiac development–related genes located on chromosome 21 affecting endocardial cushion development. In the 1980s–90s, it was established that early surgical repair can be performed safely even in AVSD patients with Down syndrome.

Since the 21st century, advances in echocardiography and cardiac MRI have greatly improved preoperative anatomical assessment and postoperative follow-up. As the problem of pulmonary hypertension (Eisenmenger physiology) in AVSD patients left uncorrected into adulthood has come to the fore, the importance of early (infancy) complete repair has been emphasized. In Korea as well, with the development of pediatric cardiac surgery, outcomes of early corrective surgery for AVSD have improved to international levels.


2. Causes

The cause of atrioventricular septal defect lies in abnormal development of the endocardial cushions, which form the lower part of the atrial and ventricular septa at embryonic weeks 4–6. Normally, the superior and inferior endocardial cushions fuse to divide the space between the primitive atrial septum and the primitive ventricular septum (the atrioventricular canal) and form the bases of the tricuspid and mitral valves. In AVSD, this fusion process is incomplete or fails, resulting in combined atrial- and ventricular-level defects and atrioventricular valve malformations.

AVSD is broadly classified into complete AVSD and partial AVSD (or ostium primum ASD). Complete AVSD is characterized by a primum defect at the atrial level, a defect at the ventricular level (inlet VSD), and a single common atrioventricular valve. The common atrioventricular valve is divided into left and right components and, depending on the extent to which the superior bridging leaflet and inferior bridging leaflet cross the ventricular septum, is subdivided into Rastelli type A (leaflet attached to the ventricular septum), type B (rare; abnormal chordae with the leaflet attached in the right ventricle), and type C (leaflet free-floating; common in Down syndrome).

Partial AVSD is characterized by a primum defect of the atrial septum and a cleft anterior mitral leaflet (cleft mitral valve), with no ventricular-level defect. Transitional AVSD is an intermediate form between the complete and partial forms. Isolated cleft mitral valve is excluded from this category.

In terms of genetic causes, AVSD is very strongly associated with Down syndrome (trisomy 21). Congenital heart disease occurs in about 40–45% of patients with Down syndrome, of which complete AVSD is the most common (about 17–19%). Conversely, about 70% of patients with complete AVSD have Down syndrome. Genes located on the long arm of chromosome 21, such as DSCAM (Down Syndrome Cell Adhesion Molecule), COL6A1, and COL6A2, are being studied in relation to endocardial cushion development. In sporadic AVSD occurring without Down syndrome, variants in the CRELD1 (2p25), GATA4, GATA6, NKX2.5, EVC, and EVC2 genes have been reported. AVSD commonly accompanies Ellis-van Creveld syndrome (EVC/EVC2 variants). Environmental causes such as diabetes during pregnancy, retinoid exposure, and rubella are known general risk factors for congenital heart disease.


3. Genetics

The genetics of atrioventricular septal defect differ greatly depending on whether Down syndrome is present. In patients with Down syndrome (trisomy 21), complete AVSD is the most common congenital heart disease, and overexpression of genes located on the long arm of chromosome 21 (21q22) is understood to cause abnormal endocardial cushion development. Studies have been published showing that the DSCAM (Down Syndrome Cell Adhesion Molecule, 21q22.2) and COL6A1/COL6A2 (type VI collagen, 21q22.3) genes play important roles in cardiac development.

For isolated AVSD without Down syndrome (non-syndromic AVSD), both familial and sporadic occurrence patterns have been reported. In familial AVSD, some pedigrees show an autosomal dominant inheritance pattern, and pathogenic variants in the following genes have been reported in non-syndromic AVSD. GATA4 (8p23.1) is a cardiac transcription factor, and heterozygous variants are associated with various congenital heart diseases including AVSD and ASD. GATA6 (18q11.2) plays a similar role and is associated with AVSD, ASD, and pulmonary artery malformations. CRELD1 (2p25.3) variants were among the first causative genes identified in non-syndromic AVSD. NKX2.5 (5q35.1) is a cardiac transcription factor associated with various congenital heart diseases. Ellis-van Creveld syndrome is caused by variants in the EVC/EVC2 genes (4p16.2), and AVSD occurs in about 50–60% of patients with this syndrome.

The familial recurrence rate is higher than in the general population; when one parent has AVSD, the recurrence risk in offspring is reported at about 10–14%. When a sibling has AVSD, the recurrence risk is about 3–5%. In Down syndrome, the recurrence risk of trisomy varies with maternal age, and when a previous child has Down syndrome there is an additional risk of about 1%. It is standard to perform chromosome analysis (karyotyping) or chromosomal microarray in all AVSD patients to identify Down syndrome and other chromosomal abnormalities. Particularly in AVSD with Down syndrome, genetic counseling of the parents regarding recurrence risk is needed.


4. General epidemiology

Atrioventricular septal defect is a relatively common form of congenital heart disease, accounting for about 4–5% of all congenital heart disease and occurring in about 1 in 2,000–5,000 live births. This figure includes both complete and partial AVSD. There is no significant sex difference in the complete form, but there are reports that the partial form (primum ASD) is slightly more common in females.

The most important epidemiological feature is the strong association with Down syndrome (trisomy 21). Congenital heart disease accompanies about 40–45% of patients with Down syndrome, of which about 40% is AVSD (including complete and partial forms). Meanwhile, about 60–70% of patients with complete AVSD have Down syndrome. These statistics mean that, as the survival of Down syndrome has improved with advances in neonatal intensive care, the absolute number of AVSD cases is also increasing.

Regarding the epidemiological situation in Korea, Health Insurance Review & Assessment Service (HIRA) data show a steady number of new patients with code Q21.2 each year, and patients registered under Special Copayment Reduction V269 receive rare disease medical cost support. AVSD with Down syndrome, unlike the partial form, tends strongly to present as the complete form and requires early surgical repair in infancy. Partial AVSD often occurs in isolation, and because of its relatively mild clinical course, diagnosis is sometimes delayed until school age or adulthood.

In patients with complete AVSD left without corrective surgery, about 50% are reported to have died of congestive heart failure before age 1 and about 80% before age 2. This is because increased pulmonary blood flow and pulmonary hypertension progress rapidly. Early surgical repair (recommended within 3–6 months of birth) is the most important factor determining survival and long-term prognosis. If left uncorrected into adulthood, Eisenmenger physiology develops and surgical repair becomes impossible.


5. Pathophysiology

The core pathophysiology of atrioventricular septal defect stems from left-to-right shunting at the atrial and ventricular levels and atrioventricular valve regurgitation. These two factors cause increased pulmonary blood flow, elevated pulmonary artery pressure, and ventricular volume overload, forming a vicious cycle that progresses to pulmonary hypertension and heart failure.

Shunting in complete AVSD: left atrium→right atrium and left ventricle→right ventricle shunts occur simultaneously through the atrial-level primum defect and the ventricular-level inlet VSD. Shunt size and direction are determined by the function of the right and left atrioventricular valves, left and right ventricular compliance, and pulmonary vascular resistance (PVR). Immediately after birth, high pulmonary vascular resistance limits the shunt, but as pulmonary vascular resistance normally falls over the first weeks to months of life, shunt volume rises sharply and pulmonary blood flow increases greatly.

Atrioventricular valve regurgitation: regurgitation of the common atrioventricular valve or the cleft anterior mitral leaflet (partial AVSD) places an additional volume load on the left ventricle and raises left atrial pressure, causing increased pulmonary venous pressure and pulmonary edema. The more severe the regurgitation, the earlier and more severe the heart failure symptoms.

Pulmonary vascular reactivity and pulmonary hypertension: persistently increased pulmonary blood flow and elevated pressure cause adverse remodeling of the pulmonary vessels. Particularly in AVSD with Down syndrome, the pulmonary vessels are more vulnerable to increased pulmonary blood flow than in normal infants, so pulmonary hypertension progresses faster. In Down syndrome, airway abnormalities (upper airway obstruction, abnormal lung development), alveolar hypoventilation, and hypoxemia further aggravate pulmonary vasoconstriction. Untreated, it progresses to Eisenmenger syndrome, in which pulmonary vascular resistance rises to systemic levels, the shunt reverses (right-to-left shunt), and cyanosis appears.

Ventricular dysfunction: a tendency toward narrowing of the left ventricular outflow tract (left ventricular outflow tract obstruction, LVOTO) structurally develops easily in AVSD. This is because the left ventricle shows a 'goose-neck' deformity due to the atrioventricular valve malformation, and residual LVOTO may remain even after surgery. Postoperative atrioventricular valve regurgitation, LVOTO, and atrioventricular block are the main factors determining long-term prognosis.


6. Symptoms

The clinical symptoms of atrioventricular septal defect vary greatly depending on whether the form is complete or partial, and on associated malformations and the degree of atrioventricular valve regurgitation.

Symptoms of complete AVSD: heart failure symptoms typically appear within weeks to months after birth. This is because, as pulmonary vascular resistance falls, a large left-to-right shunt develops and pulmonary blood flow rises sharply. Characteristic symptoms include tachypnea, poor feeding, diaphoresis, fatigue, and failure to thrive. Cyanosis is absent or mild initially but becomes evident as Eisenmenger physiology progresses. Recurrent respiratory infections are common and are sometimes the reason for the first medical visit. When Down syndrome is present, sleep apnea or upper airway obstruction due to airway abnormalities (tracheomalacia, macroglossia) may be added.

Symptoms of partial AVSD (primum ASD): symptoms vary with shunt size. With small defects, patients may be asymptomatic or have only mild exercise intolerance until school age or adulthood. With a large primum ASD, exertional fatigue, dyspnea, and recurrent pulmonary infections may occur. When cleft mitral valve regurgitation is severe, symptoms of left heart failure (dyspnea, orthopnea) appear. In uncorrected partial AVSD in adulthood, pulmonary hypertension, atrial arrhythmias (atrial fibrillation, atrial flutter), and right heart failure are important complications.

Special features of AVSD with Down syndrome: in infants with Down syndrome, pulmonary hypertension progresses faster in AVSD because of the rapid pulmonary vascular response. Cyanosis is mild or absent initially and the disease presents only as heart failure, but it can progress rapidly to Eisenmenger physiology. This is the rationale emphasizing the importance of early surgery (within 3–6 months of birth). Even after surgery, long-term follow-up for complications such as atrioventricular valve regurgitation, LVOTO, and atrioventricular block is needed.


7. Signs

The physical and test findings of atrioventricular septal defect vary depending on the complete/partial form, shunt size, degree of atrioventricular valve regurgitation, and progression of pulmonary hypertension.

Physical signs: a systolic murmur at the lower left sternal border (due to the ventricular septal defect) and a systolic murmur at the upper left sternal border due to increased pulmonary blood flow may be heard. Fixed splitting of the second heart sound (S2) suggests a left-to-right shunt at the atrial level. When atrioventricular valve regurgitation is severe, a holosystolic murmur is heard at the apex. As pulmonary hypertension progresses, P2 (pulmonary valve closure sound) is accentuated and murmur intensity decreases (the murmur disappears with Eisenmenger physiology). Cyanosis appears with severe pulmonary hypertension and may be accompanied by clubbing. Hepatomegaly and pulmonary crackles appear with heart failure.

ECG findings: left axis deviation (LAD) or a superior axis is a typical finding of AVSD, resulting from the abnormal arrangement of the atrioventricular conduction system and the deformity of the left ventricular outflow tract. An incomplete right bundle branch block (incomplete RBBB) pattern is common. First-degree atrioventricular block (prolonged PR interval) is also observed. With large shunts, right atrial enlargement and right ventricular hypertrophy findings appear. As pulmonary hypertension progresses, right ventricular hypertrophy findings become prominent.

Chest X-ray findings: cardiomegaly, increased pulmonary vascular markings (pulmonary plethora), and enlarged hilar shadows are characteristic. In Eisenmenger physiology, a 'pruning' appearance with dilated central pulmonary arteries and reduced peripheral pulmonary vascular markings is seen.

Echocardiographic findings: the location and size of atrial- and ventricular-level defects, the morphology of the common atrioventricular valve (Rastelli classification), the degree of valve regurgitation, the presence of left ventricular outflow tract obstruction, and ventricular function are comprehensively evaluated. Pulmonary artery pressure is estimated by measuring the right ventricle–pulmonary artery pressure difference (tricuspid regurgitation velocity) with Doppler.


8. Screening

Screening for atrioventricular septal defect is carried out through prenatal fetal echocardiography, newborn critical congenital heart disease (CCHD) screening programs, and the prenatal diagnostic system for Down syndrome.

Prenatal screening and fetal echocardiography: increased nuchal translucency (NT) thickness and absent nasal bone (NB) at 11–14 weeks of gestation are findings of increased risk for Down syndrome and provide grounds for detailed fetal echocardiography. AVSD is suspected when abnormalities of the four-chamber view—atrial- and ventricular-level defects, a common atrioventricular valve, abnormal cardiac axis—are found on detailed fetal echocardiography at 18–22 weeks of gestation. When diagnosed prenatally, fetal chromosome analysis by amniocentesis or chorionic villus sampling is recommended to check for Down syndrome.

Newborn CCHD screening: pulse oximetry screening measures the difference in SpO2 between the right hand (preductal) and a foot (postductal). In complete AVSD, heart failure due to a large left-to-right shunt appears first without cyanosis, so it may not be detected early by CCHD screening. However, in newborns with heart failure symptoms (tachypnea, feeding difficulty), echocardiography should be performed together with auscultation findings.

Cardiac screening in patients with Down syndrome: newborns with confirmed Down syndrome undergo echocardiography within 1–2 months of birth regardless of symptoms. This is because the frequency of congenital heart disease is high in Down syndrome (40–45%), and cardiac malformations including AVSD require early surgical repair.

When there is a family history: detailed fetal echocardiography is recommended when a parent or sibling has AVSD. When an identified gene variant such as GATA4 or CRELD1 is present, molecular genetic family testing is possible.


9. Diagnosis

Diagnosis of atrioventricular septal defect consists of imaging evaluation centered on echocardiography and identification of associated abnormalities (chromosomal, other malformations).

Transthoracic echocardiography (TTE): the cornerstone of diagnosis. Evaluates the location and size of the lower atrial septal (primum) defect, the inlet ventricular septal defect, the morphological classification of the common atrioventricular valve (Rastelli A/B/C or partial form), the degree of valve regurgitation (color Doppler, CW Doppler), the presence of left ventricular outflow tract obstruction, and left and right ventricular function. Shunt direction and size are measured by color Doppler and pulsed-wave Doppler. Pulmonary artery pressure is estimated from the peak tricuspid regurgitation velocity (TR Vmax).

Cardiac CT angiography (Cardiac CTA): used for anatomical evaluation of associated malformations (total anomalous pulmonary venous return, great vessel abnormalities, etc.), especially to confirm three-dimensional anatomy for surgical planning. Low-dose protocols are used in children to minimize radiation exposure.

Cardiac catheterization and angiography: when pulmonary hypertension is suspected (mean PA pressure > 25 mmHg), pulmonary vascular resistance (PVR) is measured and vasoreactivity testing (response to oxygen and inhaled NO) is performed. When PVR is high, this is essential for determining surgical indications. In children younger than 6 months, surgical decisions should be made with noninvasive tests alone whenever possible.

Chromosome testing: karyotyping or chromosomal microarray (CMA) is recommended in all AVSD patients. This is because confirming Down syndrome directly affects the treatment plan (rate of pulmonary hypertension progression, timing of surgery, long-term developmental plan).

Assessment of pulmonary vascular resistance: when the timing for surgery has been missed or in adult patients, PVR is measured before and after oxygen inhalation and vasodilator administration to assess progression to Eisenmenger physiology. If the PVR/SVR ratio is < 0.3 and there is vasoreactivity, surgical repair may be considered.


10. Treatment

The definitive treatment of atrioventricular septal defect is complete surgical repair, and early (infancy) surgery is key to preventing pulmonary hypertension and to long-term prognosis.

Timing of surgery: for complete AVSD, complete repair within 3–6 months of birth (at the latest by 6 months) is recommended. Patients with Down syndrome have stronger pulmonary vascular reactivity, so earlier surgery (age 3–4 months) is recommended. Partial AVSD (primum ASD) can be repaired electively at age 2–5 years when there is no large shunt.

Surgical repair methods: the most widely used methods are the modified single-patch technique and the two-patch technique. The two-patch technique closes the ventricular and atrial defects with separate patches and reconstructs the atrioventricular valve as two separate valves. The modified single-patch technique closes the ventricular defect using a single patch and fixes the atrioventricular valve to the patch, simultaneously eliminating the atrial defect; there are reports that it is advantageous in reducing left atrioventricular valve (mitral) regurgitation. Reconstruction (suturing) of the cleft anterior mitral leaflet is essential to prevent residual regurgitation. Left ventricular outflow tract obstruction is checked during surgery and corrected if necessary.

Pulmonary artery banding (PAB): when complete repair is not possible because of low birth weight, extreme prematurity, or other malformations, pulmonary artery banding is performed temporarily to restrict pulmonary blood flow and suppress progression of pulmonary hypertension, followed by complete corrective surgery.

Medical treatment: diuretics (furosemide), ACE inhibitors (captopril, etc.), and digoxin are used to control heart failure before surgery. When pulmonary hypertension is present before surgery, oxygen and pulmonary vasodilators (sildenafil, etc.) may be used temporarily. In patients who have progressed to Eisenmenger physiology, targeted therapy for pulmonary hypertension (endothelin receptor antagonists, PDE-5 inhibitors, prostacyclin analogues) helps improve quality of life and prolong survival.

Postoperative management: residual atrioventricular valve regurgitation, LVOTO, atrioventricular block (permanent pacemaker if complete atrioventricular block develops), and residual shunts are monitored long term. If atrioventricular valve regurgitation progresses, reoperation (valvuloplasty or replacement) may be needed. Surgical outcomes in patients with Down syndrome have improved to a level similar to those in non-syndromic patients.


11. Prognosis

The prognosis of atrioventricular septal defect has improved greatly when early complete corrective surgery is performed. Early mortality after complete repair at specialized pediatric cardiac surgery centers is currently reported at 1–3%.

Long-term postoperative survival: 10-year survival after early complete repair is reported at about 85–95%. Many reports indicate that the presence of Down syndrome does not greatly affect survival. The main factors affecting long-term survival are the degree of postoperative residual atrioventricular valve regurgitation, LVOTO, and pulmonary hypertension. Patients who do not undergo complete repair have a very poor prognosis once they progress to Eisenmenger physiology.

Residual atrioventricular valve regurgitation: the most common residual problem after surgery and the main reason for reoperation in long-term follow-up. The reoperation rate 10–20 years after surgery is reported at 10–15%. Left atrioventricular valve (mitral) regurgitation is the main problem, and valvuloplasty or replacement is needed if it progresses.

Left ventricular outflow tract obstruction (LVOTO): postoperative LVOTO occurs in about 5–10% and is an important complication requiring reoperation. It may occur when intraoperative correction of LVOTO is insufficient or develop anew with growth.

Atrioventricular block: the incidence of complete atrioventricular block after surgery is about 1–3%, in which case permanent pacemaker implantation is needed. Preventing injury to the atrioventricular node and bundle of His during surgery is important.

Prognosis of patients with Down syndrome: after cardiac corrective surgery, long-term survival and quality of life in patients with Down syndrome are reported to be similar to those of non-syndromic patients in terms of cardiac outcomes. Non-cardiac factors such as developmental level, thyroid dysfunction, and immune function affect overall quality of life.


12. Prevention

There is no established way to prevent atrioventricular septal defect itself, but serious complications (pulmonary hypertension, Eisenmenger physiology) can be prevented through early detection by prenatal diagnosis and early surgical repair.

Prenatal screening and diagnosis: in pregnant women of advanced maternal age or at high risk of Down syndrome, AVSD is diagnosed early during pregnancy through prenatal screening tests (serum markers, NIPT) and detailed fetal echocardiography. When diagnosed prenatally, a multidisciplinary team (obstetrics and gynecology, neonatology, pediatric cardiology, pediatric cardiac surgery) prepares the delivery plan and newborn care in advance. When Down syndrome is diagnosed prenatally, the presence of cardiac malformations must be checked by fetal echocardiography.

Cardiac screening of newborns with Down syndrome: all newborns with confirmed Down syndrome undergo echocardiography within 1–2 months of birth. This is a key preventive strategy for detecting AVSD early and planning surgical repair before pulmonary hypertension progresses (within 3–6 months of birth).

Early surgical repair: for complete AVSD, complete repair within 3–6 months of birth is the most effective preventive measure against progression of pulmonary hypertension. Parents should be fully educated that delaying surgery can lead to irreversible pulmonary vascular damage and Eisenmenger physiology.

Long-term postoperative follow-up: residual atrioventricular valve regurgitation, LVOTO, atrioventricular block, and recurrence of pulmonary hypertension are monitored regularly after surgery (echocardiography and clinical evaluation every 1–2 years in childhood and every 1–2 years in adulthood). If arrhythmias develop, Holter monitoring and antiarrhythmic treatment are provided.


13. References

  1. Bernier PL, Stefanescu A, Samoukovic G, Tchervenkov CI. The challenge of congenital heart disease worldwide: epidemiologic and demographic facts. Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu. 2010;13(1):26-34. DOI: 10.1053/j.pcsu.2010.02.005. PMID: 20307858.

  2. Jacobs JP, Burke RP, Quintessenza JA, Mavroudis C. Congenital Heart Surgery Nomenclature and Database Project: atrioventricular canal defect. Ann Thorac Surg. 2000;69(4 Suppl):S36-S43. DOI: 10.1016/S0003-4975(99)01278-5. PMID: 10798430.

  3. Calabrò R, Limongelli G. Complete atrioventricular canal. Orphanet J Rare Dis. 2006;1:8. DOI: 10.1186/1750-1172-1-8. PMID: 16722617.

  4. Formigari R, Michielon G, Digilio MC, et al. Genetic syndromes and congenital heart defects: how is surgical management affected? Eur J Cardiothorac Surg. 2009;35(4):606-614. DOI: 10.1016/j.ejcts.2008.12.023. PMID: 19232495.

  5. Rastelli G, Kirklin JW, Titus JL. Anatomic observations on complete form of persistent common atrioventricular canal with special reference to atrioventricular valves. Mayo Clin Proc. 1966;41(5):296-308. PMID: 5941797.

  6. Michielon G, Stellin G, Rizzoli G, et al. Left atrioventricular valve incompetence after repair of common atrioventricular canal defects. Ann Thorac Surg. 1995;60(6 Suppl):S604-S609. DOI: 10.1016/0003-4975(95)00785-7. PMID: 8604952.

  7. Sridhar A, Subramaniam M, Sudhakar A, et al. Repair of complete atrioventricular septal defect in patients less than 3 months: early and mid-term results. World J Pediatr Congenit Heart Surg. 2016;7(4):462-467. DOI: 10.1177/2150135116638867. PMID: 27371757.

  8. Ramsay JM, Macartney FJ, Haworth SG. Tetralogy of Fallot with complete atrioventricular septal defect. Br Heart J. 1985;53(3):266-271. DOI: 10.1136/hrt.53.3.266. PMID: 3985238.

  9. Stout KK, Daniels CJ, Aboulhosn JA, et al. 2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease. J Am Coll Cardiol. 2019;73(12):e81-e192. DOI: 10.1016/j.jacc.2018.08.1029. PMID: 30121239.

  10. Lange R, Burri M, Eschertzhuber S, et al. Atrioventricular septal defect surgery: outcome and pulmonary vascular disease. Eur J Cardiothorac Surg. 2007;32(6):1096-1102. DOI: 10.1016/j.ejcts.2007.09.012. PMID: 17919916.